NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News $56.50 -0.37 (-0.65%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$55.55▼$56.9750-Day Range$50.78▼$64.6152-Week Range$31.21▼$65.89Volume81,000 shsAverage Volume120,213 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice Target$71.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ANI Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside26.8% Upside$71.67 Price TargetShort InterestHealthy1.51% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews Sentiment1.12Based on 7 Articles This WeekInsider TradingSelling Shares$27.02 M Sold Last QuarterProj. Earnings Growth9.46%From $3.17 to $3.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.63 out of 5 starsMedical Sector100th out of 966 stocksPharmaceutical Preparations Industry26th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.67, ANI Pharmaceuticals has a forecasted upside of 26.8% from its current price of $56.50.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.51% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 15.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 2.8 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ANI Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,018,754.00 in company stock.Percentage Held by Insiders28.50% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.78% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 9.46% in the coming year, from $3.17 to $3.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -117.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -117.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ANI Pharmaceuticals (NASDAQ:ANIP) StockANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesOctober 2, 2023 | markets.businessinsider.comANI Pharmaceuticals Gets FDA Nod For Cortrophin Gel 1-mL VialOctober 2, 2023 | finance.yahoo.comANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis FlaresOctober 4, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!October 2, 2023 | americanbankingnews.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Up 15.7% in SeptemberSeptember 22, 2023 | finance.yahoo.comMirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?September 20, 2023 | finance.yahoo.comANI Pharmaceuticals (ANIP) Stock Moves -0.9%: What You Should KnowSeptember 18, 2023 | finance.yahoo.comANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023September 13, 2023 | markets.businessinsider.comAnalyst Expectations for ANI Pharmaceuticals's FutureOctober 4, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 12, 2023 | finanznachrichten.deANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USPSeptember 12, 2023 | finance.yahoo.comANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USPSeptember 12, 2023 | seekingalpha.comANI Pharma: Slow And Steady Revenue GeneratorSeptember 12, 2023 | seekingalpha.comANI Pharma: Slow And Steady Revenue GeneratorSeptember 8, 2023 | finance.yahoo.comANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's WhySeptember 1, 2023 | msn.comANI Pharmaceuticals (ANIP) Price Target Increased by 18.13% to 73.10August 28, 2023 | nasdaq.comANI Pharmaceuticals Announces Approval, Launch Of Estradiol Gel, 0.1%August 28, 2023 | seekingalpha.comANI Pharma granted FDA nod for generic Estradiol GelAugust 28, 2023 | finance.yahoo.comANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%August 25, 2023 | finance.yahoo.comWhat Makes ANI (ANIP) a New Strong Buy StockAugust 24, 2023 | finance.yahoo.comANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | finance.yahoo.comHere's Why Momentum in ANI (ANIP) Should Keep goingAugust 23, 2023 | finanznachrichten.deANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of DirectorsAugust 23, 2023 | finance.yahoo.comANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of DirectorsAugust 22, 2023 | nasdaq.comTruist Securities Reiterates ANI Pharmaceuticals (ANIP) Buy RecommendationAugust 21, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About ANI PharmaceuticalsAugust 16, 2023 | finance.yahoo.comEton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?August 10, 2023 | finance.yahoo.comANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?See More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Company Calendar Last Earnings8/09/2023Today10/03/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year FoundedN/APrice Target and Rating Average Stock Price Forecast$71.67 High Stock Price Forecast$73.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+26.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E Ratio17.82 P/E GrowthN/ANet Income$-47,900,000.00 Net Margins-1.29% Pretax Margin-2.62% Return on Equity15.77% Return on Assets6.81% Debt Debt-to-Equity Ratio0.70 Current Ratio3.74 Quick Ratio2.89 Sales & Book Value Annual Sales$316.39 million Price / Sales3.62 Cash Flow$3.93 per share Price / Cash Flow14.38 Book Value$17.92 per share Price / Book3.15Miscellaneous Outstanding Shares20,290,000Free Float14,509,000Market Cap$1.15 billion OptionableOptionable Beta1.06 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 45)Pres, CEO & Director Comp: $1.31MMr. Stephen P. Carey (Age 52)Sr. VP of Fin. & CFO Comp: $751kMr. James G. Marken (Age 60)Sr. VP of Operations & Product Devel. Comp: $673.23kMr. Christopher K. Mutz (Age 51)Head of Rare Disease Comp: $565.17kMr. Ori Gutwerg (Age 49)Sr. VP of Generics Comp: $623.89kMr. Muthusamy Shanmugam MS R.Ph. (Age 55)Head of R&D, COO of Novitium Operations & Director Ms. Meredith W. Cook (Age 49)Sr. VP, Gen. Counsel & Corp. Sec. Mr. Chad Gassert (Age 47)Sr. VP of Corp. Devel. & Strategy Ms. Krista L. Davis (Age 50)Chief HR Officer Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseMore ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTX89bioNASDAQ:ETNBAurinia PharmaceuticalsNASDAQ:AUPHBiohavenNYSE:BHVNKiniksa PharmaceuticalsNASDAQ:KNSAView All CompetitorsInsiders & InstitutionsChad GassertSold 20,000 sharesTotal: $1.13 M ($56.48/share)Barclays PLCBought 498 shares on 9/21/2023Ownership: 0.038%Muthusamy ShanmugamSold 8,425 sharesTotal: $519,317.00 ($61.64/share)Muthusamy ShanmugamSold 16,242 sharesTotal: $1.02 M ($62.81/share)Chad GassertSold 20,000 sharesTotal: $1.29 M ($64.70/share)View All Insider TransactionsView All Institutional Transactions ANIP Stock - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price forecast for 2023? 3 brokerages have issued 12-month price objectives for ANI Pharmaceuticals' shares. Their ANIP share price forecasts range from $70.00 to $73.00. On average, they expect the company's stock price to reach $71.67 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2023? ANI Pharmaceuticals' stock was trading at $40.23 at the beginning of 2023. Since then, ANIP shares have increased by 40.4% and is now trading at $56.50. View the best growth stocks for 2023 here. Are investors shorting ANI Pharmaceuticals? ANI Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 306,500 shares, an increase of 15.7% from the August 31st total of 264,800 shares. Based on an average daily trading volume, of 155,800 shares, the days-to-cover ratio is currently 2.0 days. View ANI Pharmaceuticals' Short Interest. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our ANIP earnings forecast. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its earnings results on Wednesday, August, 9th. The specialty pharmaceutical company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.64. The specialty pharmaceutical company earned $116.50 million during the quarter, compared to analyst estimates of $99.87 million. ANI Pharmaceuticals had a negative net margin of 1.29% and a positive trailing twelve-month return on equity of 15.77%. The firm's revenue for the quarter was up 57.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.05) EPS. What ETFs hold ANI Pharmaceuticals' stock? ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, August, 30th. The company provided EPS guidance of $3.62-4.11 for the period, compared to the consensus EPS estimate of $3.97. The company issued revenue guidance of $425-445 million, compared to the consensus revenue estimate of $442.79 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). What is ANI Pharmaceuticals' stock symbol? ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP." How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ANI Pharmaceuticals' stock price today? One share of ANIP stock can currently be purchased for approximately $56.50. How much money does ANI Pharmaceuticals make? ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $1.15 billion and generates $316.39 million in revenue each year. The specialty pharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. How many employees does ANI Pharmaceuticals have? The company employs 600 workers across the globe. How can I contact ANI Pharmaceuticals? ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540. This page (NASDAQ:ANIP) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.